Home › NDC Lookup › RxCUI directory › RxCUI 313428

Toremifene 60 MG Oral Tablet — RxCUI 313428

RxNorm drug concept · Semantic clinical drug
RxCUI 313428 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI313428
Official nameToremifene 60 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astoremifene (as toremifene citrate 88.5 MG) Oral Tablet; toremifene citrate 60 MG Oral Tablet
FDA products mapped3
Package NDCs mapped4
Reported Medicaid activity (SDUD)60 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Toremifene: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats metastatic breast cancer in postmenopausal women whose tumors are estrogen-receptor positive or unknown. It works by blocking estrogen's growth-promoting effect on the ca...
  • Take one tablet by mouth once a day, with or without food. You'll generally keep taking it until your doctor sees the cancer progressing. Follow your prescription label.
  • The common ones are hot flashes, sweating, nausea, and vaginal discharge. Dizziness, swelling, and vomiting also occur. These often show up early in treatment.
  • Toremifene can lengthen the QT interval, a heart rhythm change that can cause fainting, seizures, or death. Call for help if you faint or have a racing, irregular heartbeat. Your d...
📖 Read our full Toremifene guide →

🕸️ Concept Web — How Toremifene 60 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Toremifene 60 MG Oral Tablet RxCUI 313428

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Toremifene 38409
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Fareston 155082
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Toremifene Oral Tablet 374167
    • Toremifene Oral Product 1157658
    • Toremifene Pill 1157659
    • Toremifene Oral Tablet [Fareston] 368304
    • Fareston Oral Product 1174686
    • Fareston Pill 1174687
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Toremifene 60 MG SCDC · 330281
  • Toremifene Oral Tablet SCDF · 374167
  • Toremifene Oral Product SCDG · 1157658
  • Toremifene Pill SCDG · 1157659

Brand-Name Concepts

  • Toremifene 60 MG Oral Tablet [Fareston] SBD · 152880
  • Toremifene 60 MG [Fareston] SBDC · 565092
  • Toremifene Oral Tablet [Fareston] SBDF · 368304
  • Fareston Oral Product SBDG · 1174686
  • Fareston Pill SBDG · 1174687
  • Fareston BN · 155082

📦 FDA Products & Package NDCs

3 products · 4 package NDCs
4 package NDCs map to RxCUI 313428 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
42747-0327-30 30 TABLET in 1 BOTTLE (42747-327-30) Fareston Kyowa Kirin, Inc. 1997-06-30
42747-0327-72 7 TABLET in 1 BLISTER PACK (42747-327-72) Fareston Kyowa Kirin, Inc. 1997-06-30
64980-0404-03 30 TABLET in 1 BOTTLE, PLASTIC (64980-404-03) toremifene citrate Rising Pharma Holdings, Inc. 2019-01-18
72205-0050-30 30 TABLET in 1 BOTTLE (72205-050-30) toremifene citrate Novadoz Pharmaceuticals LLC 2020-09-02
Observed labelers: Kyowa Kirin, Inc. (2) · Novadoz Pharmaceuticals LLC (1) · Rising Pharma Holdings, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$24.6080
Range $24.6080–$24.6080 · middle 50% $24.6080–$24.6080 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.